Where I see patients (1)
Structural surfaceomics reveals an AML-specific conformation of integrin ß2 as a CAR T cellular therapy target.
Innovating Simpler and Less Toxic Frontline Management for Adults With ALL.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab.
Therapeutic advances in hematology
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Overall survival post-alloHCT via comparison between those testing positive or negative using an optimized molecular monitoring approach.
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Grade >= 3 toxicity using Common Terminology Criteria for Adverse Events version 5.0 or severe persistent hematologic toxicity defined as absolute neutrophil count (ANC) < 500/uL OR platelet count < 10,000/uL in participants that ...